Description In vitro In vivo References
ChemicalBook > CAS DataBase List > SRT1720

SRT1720

Description In vitro In vivo References
Product Name
SRT1720
CAS No.
1001645-58-4
Chemical Name
SRT1720
Synonyms
CS-233;SRT1720;STR1720;Span 55;CAY10559;CAY-10559;CAY 10559;SIRT 1933;SIRT-1933;SIRT1933.
CBNumber
CB32512407
Molecular Formula
C25H24ClN7OS
Formula Weight
506.03
MOL File
1001645-58-4.mol
More
Less

SRT1720 Property

Melting point:
>205°C (dec.)
Density 
1.58
storage temp. 
= -70C
solubility 
Soluble in DMSO (>25 mg/ml)
form 
Liquid
color 
White
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
5.30748
Product name
InSolution SRT1720, HCl - CAS 1001645-58-4 - Calbiochem
Purity
A 25 mM (10 mg/650 μl) sterile-filtered solution of SRT1720, HCl in DMSO.
Packaging
10MG
Price
$264
Updated
2024/03/01
Cayman Chemical
Product number
10011020
Product name
SRT 1720 (hydrochloride)
Purity
≥98%
Packaging
1mg
Price
$39
Updated
2024/03/01
Cayman Chemical
Product number
10011020
Product name
SRT 1720 (hydrochloride)
Purity
≥98%
Packaging
5mg
Price
$126
Updated
2024/03/01
Cayman Chemical
Product number
10011020
Product name
SRT 1720 (hydrochloride)
Purity
≥98%
Packaging
10mg
Price
$210
Updated
2024/03/01
Cayman Chemical
Product number
10011020
Product name
SRT 1720 (hydrochloride)
Purity
≥98%
Packaging
50mg
Price
$847
Updated
2024/03/01
More
Less

SRT1720 Chemical Properties,Usage,Production

Description

SRT1720 is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3.

In vitro

The maximum activation ratio of SRT1720 versus the closest sirtuin homologues, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%. SRT1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. SRT1720 could reduce fed glucose levels. Glucose excursion during an intraperitoneal glucose tolerance test is also significantly reduced in the SRT1720 group, and comparable to rosiglitazone, a PPARγ activator that has been used to treat type 2 diabetes. SRT1720 does not have an effect on fasting glucose in chow-fed mice, revealing that pharmacological SIRT1 activation is unlikely to induce hypoglycaemia. SRT1720 significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing increased insulin levels similar to rosiglitazone treatment. SRT1720 treatment increases mitochondrial capacity by 15% in gastrocnemius muscle as measured by citrate synthase activity. Higher concentrations of SRT1720 (15 μM) induces a modest (10-20%) decrease in normal cell viability. SRT1720 also significantly inhibits VEGF-dependent MM cell migration.

In vivo

In DIO mice SRT1720 mimics several of the effects observed after calorie restriction including improved insulin sensitivity, normalized glucose and insulin levels, and increased mitochondrial capacity. In addition, in diet-induced obese and genetically obese mice, SRT1720 improves insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes. Consistent with improved glucose tolerance, the glucose infusion rate required to maintain euglycaemia is approximately 35% higher in SRT1720-treated fa/fa rats, and the total glucose disposal rate is increased by approximately 20%. SRT1720 also prevents multiple myeloma tumor growth. SRT1720 increases the cytotoxic activity of bortezomib or dexamethasone.

References

http://www.selleckchem.com/products/SRT1720.html

Description

SRT1720 (1001645-58-4) is a SIRT1 activator (EC1.5 = 0.16 μM, max activation = 781%).1 It reduced glucose levels and hyperinsulinemia in DIO, Lepob/ob mice and Zucker fa/fa rats.? SRT1720 enhanced endurance running and protected against diet-induced obesity and insulin resistance via enhancement of oxidative metabolism in skeletal muscle, liver, and brown adipose tissue.2 It induced mitochondrial biogenesis in oxidant-induced renal proximal tube cell injury.3 SRT1720 repressed circadian clock gene expression and decreased H3 K9/K14 acetylation in a time-specific manner.4 It attenuated angiotensin II-induced atherosclerosis by inhibiting the vascular inflammatory response.5

Uses

SRT1720 acts as a therapeutic in the treatment of type 2 diabetes. It modulates calories and contributes to glucose homeostasis and insulin sensitivity.

General Description

An enhanced aqueous soluble version of SRT1720 (Cat. No. 567860).

Biochem/physiol Actions

Cell permeable: yes

target

SIRT1

References

Milne et al. (2007), Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes; Nature 450 712 Feige et al. (2008), Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation; Cell Metab. 8 347 Funk et al. (2010), SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells; J. Pharmacol. Exp. Ther. 333 593 Bellet et al. (2013), Pharmacological modulation of circadian rhythms by synthetic activators of the deacetylase SIRT1; Proc. Natl. Acad. Sci. USA 110 3333 Chen et al. (2015), The Sirt1 activator SRT1720 attenuates angiotensin II-induced atherosclerosis in apoE-/- mice through inhibiting vascular inflammatory response; Biochem. Biophys. Res. Commun. 465 732

SRT1720 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

SRT1720 Suppliers

Novachemistry
Tel
44-20819178-90 02081917890
Fax
(0)2080432064
Email
info@novachemistry.com
Country
United Kingdom
ProdList
4381
Advantage
58
More
Less

View Lastest Price from SRT1720 manufacturers

Career Henan Chemical Co
Product
SRT1720 1001645-58-4
Price
US $1000.00/KG
Min. Order
1G
Purity
99%
Supply Ability
100kg
Release date
2018-08-04

1001645-58-4, SRT1720Related Search:


  • N-(2-(3-(piperazin-1-ylMethyl)iMidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxaMide hydrochloride
  • SRT1720
  • N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide hydrochloride
  • SRT1720HCL
  • SRT 1720 (Hydrochloride)
  • N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide hydrochloride SRT 1720
  • SRT-1720 xhydrochloride
  • SRT1720 hydrochloride, >=98%
  • CAY 10559
  • CAY10559
  • CAY-10559
  • SIRT 1933
  • SIRT-1933
  • SIRT1933.
  • SRT-1720 HCl, SRT-1720 hydrochloride
  • SRT-1720 HCL, SRT-1720 HYDROCHLORIDE; SRT1720; SRT-1720; SRT 1720; CAY10559; CAY-10559; CAY 10559; SIRT-1933; SIRT 1933; SIRT1933.
  • N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide,hydrochloride
  • STR1720
  • CS-233
  • SRT 1720 tetrahydrochloride
  • SRT1720;SRT-1720
  • N-(2-(3-(Piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide hydr
  • SRT1720 USP/EP/BP
  • SRT1720 HCL (CAY-10559)
  • Emsorb 2505
  • Liposorb S-20
  • Sorbon S 60
  • Span 55
  • N-(2-(3-(Piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide xhydrochloride
  • SRT-1720 HCl SRT1720 HCl
  • SRT-1720 hydrochloride,SRT1720 hydrochloride
  • 1001645-58-4
  • C25H23N7OSHCl
  • C25H24ClN7OS
  • Inhibitor
  • Inhibitors